Background
Selective estrogen receptor modulators (SERMs) such as Tamoxifen (TAM) can significantly improve breast cancer-specific survival for women with ER-positive (ER+) disease. However, resistance to TAM remains a major clinical problem. The resistant phenotype is usually not driven by loss or mutation of ER; instead, changes in multiple proliferative and/or survival pathways override the inhibitory effects of TAM. Estrogen-related receptor gamma (ERRγ) is an orphan member of the nuclear receptor superfamily that promotes TAM resistance in ER+ breast cancer cells. In this study, we sought to clarify the mechanism(s) by which this orphan nuclear receptor is regulated and, in turn, affects TAM resistance.
Methods
mRNA and protein expression/phosphorylation were monitored by RT-PCR and Western blotting, respectively. Site-directed mutagenesis was used to disrupt consensus ERK target sites. Cell proliferation and cell cycle progression were measured by flow cytometric methods. ERRγ transcriptional activity was assessed by dual-luciferase promoter-reporter assays.
Results
We show that ERRγ protein levels are affected by the activation state of ERK/MAPK, and mutation of consensus ERK target sites impairs ERRγ-driven transcriptional activity and TAM resistance.
Conclusions
These findings shed new light on the functional significance of ERRγ in ER+ breast cancer, and are the first to demonstrate a role for kinase regulation of this orphan nuclear receptor.
Orphan receptors comprise nearly half of all members of the nuclear receptor superfamily.
Despite having broad structural similarities to the classical estrogen receptors,
estrogen-related receptors (ERRs) have their own unique DNA response elements and
functions. In this study, we focus on 2 ERRβ splice variants, short form ERRβ
(ERRβsf) and ERRβ2, and identify their differing roles in cell cycle regulation.
Using DY131 (a synthetic agonist of ERRβ), splice-variant selective shRNA, and
exogenous ERRβsf and ERRβ2 cDNAs, we demonstrate the role of ERRβsf in
mediating the G1 checkpoint through p21. We also show ERRβsf is required for
DY131-induced cellular senescence. A key novel finding of this study is that ERRβ2
can mediate a G2/M arrest in response to DY131. In the absence of ERRβ2, the
DY131-induced G2/M arrest is reversed, and this is accompanied by p21 induction and a G1
arrest. This study illustrates novel functions for ERRβ splice variants and provides
evidence for splice variant interaction.
The p53 tumor suppressor protein plays a crucial role in influencing cell fate decisions in response to cellular stress. As p53 elicits cell cycle arrest, senescence or apoptosis, the integrity of the p53 pathway is considered a key determinant of anti-tumor responses. p53 can also promote autophagy, however the role of p53-dependent autophagy in chemosensitivity is poorly understood. VMY-1-103 (VMY), a dansylated analog of purvalanol B, displays rapid and potent anti-tumor activities, however the pathways by which VMY works are not fully defined. Using established prostate cancer cell lines and novel conditionally reprogrammed cells (CRCs) derived from prostate cancer patients; we have defined the mechanisms of VMY-induced prostate cancer cell death. Herein, we show that the cytotoxic effects of VMY required a p53-dependent induction of autophagy, and that inhibition of autophagy abrogated VMY-induced cell death. Cancer cell lines harboring p53 missense mutations evaded VMY toxicity and treatment with a small molecule compound that restores p53 activity re-established VMY-induced cell death. The elucidation of the molecular mechanisms governing VMY-dependent cell death in cell lines, and importantly in CRCs, provides the rationale for clinical studies of VMY, alone or in combination with p53 reactivating compounds, in human prostate cancer.
Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological, and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC). Mounting evidence suggests that estrogen receptor-alpha positive (ER+) ILC has a poor response to Tamoxifen (TAM), but the mechanistic drivers of this are undefined. In the current work, we comprehensively characterize the SUM44/LCCTam ILC cell model system through integrated analysis of gene expression, copy number, and mutation, with the goal of identifying actionable alterations relevant to clinical ILC that can be co-targeted along with ER to improve treatment outcomes. We show that TAM has several distinct effects on the transcriptome of LCCTam cells, that this resistant cell model has acquired copy number alterations and mutations that impinge on MAPK and metabotropic glutamate receptor (GRM/mGluR) signaling networks, and that pharmacological inhibition of either improves or restores the growth-inhibitory actions of endocrine therapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.